

Subject Enrollment Strategy Forum

Cyril Ofori, MD, FACC Wooster Hospital, CHANGE AFib High Enrolling Site PI

Matthew Kalscheur, MD University Wisconsin-Madison, CHANGE AFib Steering Committee Member

Sean Pokorney, MD, MBA Duke University, CHANGE AFib Steering Committee Member

Disclosures

- Cyril Ofori Disclosure: None
- Matthew Kalscheur Disclosure: None
- Sean Pokorney Disclosure:

Research grant support from: Food and Drug Administration, Janssen Pharmaceuticals, Bristol-Myers Squibb, Pfizer, Gilead, Philips, Sanofi, Boston Scientific, 4D Molecular Therapeutics, Lexeo Therapeutics, and Medtronic

Consultant/Advisory Board support from: Boston Scientific, Medtronic, Bristol-Myers Squibb, Pfizer, Philips, Milestone, Sanofi, and Zoll







Key Objectives

- 1. Trial Site Characteristics
- 2. Enrollment Workflows
- 3. Patient Identification & Trial Engagement
- 4. Engaging Providers Across the Health System
- 5. Navigating Treatment Plans & Addressing Comorbidities
- 6. Subject & Study Drug Retention
- 7. Q&A



Trial Site Characteristics



Hospital: Wooster Community Hospital
Location: Wooster, OH
PI: Dr. Cyril Ofori
Study Coordinator: Erica Stahl, MSN,
RN, APRN-AGCNS-BC



Site Characteristics:

- 172 bed, community hospital
- Activated in Trial = April 8, 2022
- DOA Composition: PI & 2 Study Coordinators
- 22 Enrolled Subjects; 68% from OP Setting



UWHealth

Hospital: University Hospital - University of Wisconsin-Madison Location: Madison, WI PI: Dr. Matthew Kalscheur Study Coordinator: Emily Sherrick, BS, CMA (AAMA)



Site Characteristics:

- 515 bed academic hospital
- Activated in Trial = November 22, 2023
- DOA Compositionn: PI, Sub-I and 2 Study Coordinators
- 6 Enrolled Subjects; 100% from OP Setting



Enrollment Workflows

Wooster Community Hospital Enrollment Workflows

Overall Tactics

- / Daily Screening: *trial kept at forefront*
 - AFIB census report of all AFIB Dx pts, RN documentation or AF telemetry rhythm
- / Continuous team communication
- / Team approach: discuss/review subjects, consent conversations, etc.
- / Peer trial education to units with AFIB pt potential

Consent Conversations

- / Building patient trust and rapport
- / Initial approach by RN
- / Stress medication history (FDA approved) and previous use in providers clinic
- / Involve Family/Spouse
- / Medication interactions and risk assessment



University Hospital – University of Wisconsin-Madison Enrollment Workflows

Overall Tactics

- Screening conducted via EMR logic notifying research team via InBasket Message (EPIC EMR)
- / Potentially eligible patients are placed on a shared EMR list for PI review
- / PI confirmation of eligibility triggers message to patient's provider to discuss trial participation.
- / Upon provider permission, outreach to patient is conducted by PI.
- / Research team conducts follow-up to confirm potential study participation and provides additional study information.

Recruitment Strategies

- / EMR Based Workflows
- / Trial visibility reminders and engagement with ED & Cardiology colleagues








Patient Identification & Trial Engagement

Patient Identification & Trial Engagement

- Catching ED patients prior to discharge
- Identifying inpatients prior to care plan establishment
 - /Working in OP setting with general cardiology
- Identifying outpatients
- Manual screening practices & leveraging **EMRs**



Engaging Providers Across the Health System

CHANGE

Engaging Providers Across the Health System

- Increasing trial visibility and collaboration with other departments (ED, Outpatient, ICU, etc.)
- Familiarity with Dronedarone amongst non-trial colleagues
- Bi-directional communication between General Cardiology & EPs on treatment plans and subject identification
- Pharmacy Team engagement



Navigating **Treatment Plans** 8 Addressing Comorbidities



Navigating Treatment Plans & Addressing Comorbidities

- Study Drug Interactions, Contraindications & Adverse Reactions
- Renal Function
- Patient's Age
- Bradycardia

Heart Failure Classifications & AFlutter






Subject & Study Drug Retention

Subject & Study Drug Retention

- Open line of communication between subject & research team
- Outreach to subject's treatment teams for continuity of care and study drug retention
- Organizational processes to prevent LTFUs







Questions from the Group?



Cyril Ofori, MD, FACC Wooster Community Hospital <u>cofori@woosterheartgroup.com</u>

Matthew Kalscheur, MD University Hospital - University of Wisconsin-Madison <u>mmkalsch@medicine.wisc.edu</u>

Sean Pokorney, MD, MBA Duke University <u>sean.pokorney@duke.edu</u>



Thank You



Appendix

UW Health: Workflow - BPA

Logic:

(NOT 1 AND NOT 2 AND NOT 3) AND (4 AND (5 AND 6 AND 7 AND 8) AND ((9 AND (10 OR 11)) OR (12 AND (10 OR 13)))

- 1. HAS FIRED AFTER GO LIVE [7000269]
- 2. PATIENT ALREADY ASSOCIATED WITH STUDY [7000272]
- 3. 148 DX PRIOR TO 90 DAYS AGO [7000265]
- 4. EXCLUDE WHEN STUDY IS NOT RECRUITING [7000271]
- 5. PATIENT IS ALIVE [4573]
- 6. AGE >= 21 [7000261]
- 7. PATIENT TYPE NOT DCFS DOC OR MMHI [7000210]
- 8. EJECTION FRACTION >40 OR NULL [7000263]
- 9. CURRENTLY ADMITTED TO UH OR EMH LESS THAN 7 DAYS [7000267]
- 10. I48 DX IN PAST 90 DAYS [7000264]
- 11. AFIB CONSULT OR ORDER SET USED IN PAST 6 DAYS [7000266]
- 12. ADMITTED IN PAST 90 DAYS TO UH OR EMH FOR LESS THAN 7 DAYS [7000268]
- 13. AFIB CONSULT OR ORDER SET USED IN PAST 41 DAYS [7000262]



- Step 1: Patient has not been identified already and does not have diagnosis of AFib (I.48 in problem list or visit diagnosis)
- Step 2: Age and EF eligible
- Step 3: Acute care encounter and AFib identified (I.48 or certain orders placed)





UW Health: CHANGE AFib – Provider Message

				Smart
In Basket				Manag
III Dasket				RESEA
← → 🏠 Home 🤁 R <u>e</u> fresh	🛱 New Message	•	New Patient N	
My Messages	1 Note to Research RN			
	1 2 CHANGE AFib Message to PCP			


© 2023 Epic Systems Corporation

① Do not include PHI or patient-specific data in SmartPhrases.	🀐 Settings
 ★ B ⊕ ♥ ▷ ♀ + Insert SmartText ⇔ ⇒ ⇒ Insert SmartList ≡ ★ + → ⇒ ★ + → → ⇒ ★ + → ⇒ ★ + → ⇒ ★ + → ⇒ ★ +	Name RESEARCHCHANGEAFIBPCPCONTACT Description Populate from Text Contacting PCP to Ask about CHANGE-AFib Text Format Rich Text Plain Text SmartLink Text Size and Font (?)
The idea is that AF is progressive. Observational data suggests that earlier rhythm control leads to improved outcomes (less health care utilization, improve symptoms, etc.). The AHA and Duke Clinical Research Institute are running this pragmatic trial to study this idea in a randomized, controlled trial. If a patients choose to enroll, they will be randomized to usually care (rate control + anticoagulation if appropriate) versus early rhythm control (usual care + dronedarone). Outcomes will be tracked through the AHA-GWTG registry and some patient reported outcomes.	Match Template Formatting Keep SmartLink Formatting Synonyms * Sharing You are an editor
Would you be okay with us contacting your patient? I'd be happy to talk with you more about the trial - cell is 608-334-0664 or over email, mmkalsch@medicine.wisc.edu. Thanks! Matt	User Can Edit? 1 KALSCHEUR, MATTHEW M [MXK206] 2 0 2 0 \$\mathcal{L}\$, Copy Users Mark All as Editors



UWHealth

UW Health: CHANGE AFib – Patient Message



UW Health: CHANGE AFib – Shared List

Patient Lists ∦ E <u>d</u> it List → 🛛 — Remo <u>v</u> e Patient 🕂 <u>A</u> dd	Patient 🚰 Open Chart 📮 Patient Report 📮 Reports 🗸 💉 Sign In 🔌 Sign Out 🚦	IP Treatment Team ▼ → Wrap Text	© 🔁 💥 ☆ ⊕
My Lists	potential CHANGE AFIB 3 Patients		Refreshed 1 minute ago 🕃 Search Admissions S 🔹
Patient Name	Last EF	Specialty Comments	Specialty Comments
Zztestec, Andes M	60 % at 03/17/23 1033		needs MK review
Zztestec, Bucks	60 % at 11/04/22 1214		MK Called and sent MyChart, EW to follow-up
Zzzkalscheur, Testpatient1	—	3	EW LMTCB 3/22
P Notes	Summary Keview Results Review		

• Until patient enrolled, EW and MK communicate via Shared List



UWHealth